Burford Capital. Arbitration judgement shows value of patience. 24 th July 2017

Size: px
Start display at page:

Download "Burford Capital. Arbitration judgement shows value of patience. 24 th July 2017"

Transcription

1 24 th July 2017 Financials Daily BURF.L Line, BURF.L, Trade Price(Last), 26/01/2017, 637.0, -11.0, (-1.71%) Market data Source: Thomson Reuters Eikon EPIC/TKR BUR Price (p) m High (p) m Low (p) Shares (m) Mkt Cap ( m) 1,978 Total Assets ($m) 1,050 Free Float* 86% Market AIM *As defined by AIM Rule 26 Description Burford Capital is a leading global finance and professional services firm focusing on law. Its businesses include litigation finance and risk management, asset recovery and a wide range of legal finance and advisory activities. Company information CEO CIO Chairman Key shareholders Christopher Bogart Jonathan Molot Sir Peter Middleton +1 (212) Directors 14.0% Invesco Perpetual 25.0% Woodford Investments 10.0% Aberdeen Asset Management 4.9% Next event 27/01/ /01/2017 (LON) F M A M J J A S O N D J F M A M J J A S O N D J Q Q Q Q Q Q Q Q Jul 2017 Interim results Analyst Price GBp Brian Moretta bm@hardmanandco.com Auto Burford Capital Arbitration judgement shows value of patience On Friday a positive judgement was received in one of Burford s long standing arbitration cases. In the claim by Teinver S.A. and others against Argentina, an award of $324m plus interest was made. While there are several factors to be resolved, Burford estimate their share of the award at around $140m, subject to an ongoing compound interest calculation. This compares with a current investment of $13m and an approximated balance sheet value of $30m. Although the company has yet to discuss with their auditors, they note that booked gain will not approach the full $110m difference in their year end financials. Caveats: We understand that a decision about whether to appeal will be taken in the next 90 days. It is not certain that this will happen, but if it does, then the appeal court may change the amount of the award or even reverse the decision. Effect on forecasts: With the interim figures coming out on Thursday and our forecast already including significant approximations for the Petersen case and assumed gains, we have not made any adjustment to our 2017E forecasts for now. Valuation: Although our estimates for future years have seen smaller upgrades than 2017E, Burford remains good value. The P/E for 2018E is only 18.5 times. The 2018E RoE becomes 15.9% on a larger book value, with strong growth which suggests excellent metrics all round. Risks: The investment portfolio is diversified, with exposure to over 500 claims, but retains some very large investments, which means revenue may be volatile. As the company matures, we would expect that volatility decrease, but not to disappear. The Teinver case shows that this volatility is not simply a negative. Investment summary: Burford has already demonstrated an impressive ability to deliver good returns in a growing market while investing its capital base. As the invested capital continues to grow, the litigation investment business will continue to produce strong earnings growth. Financial summary and valuation Year end Dec ($m) E 2018E 2019E Revenue Operating Profit Reported net income Underlying net income Underlying Return on Equity 12.1% 16.0% 22.2% 35.8% 15.9% 16.6% Underlying EPS ($) Statutory EPS ($) Dividend per share ($) Yield 0.6% 0.7% 0.8% 0.9% 1.0% 1.2% NAV per share ($) P/E (x) (underlying) Price/NAV (x) Source: Hardman & Co

2 Revenue Revenue ($m) E 2018E 2019E Long term growth depends on pace of investment and outcomes Accelerated investment in 2016 will boost 2017 and 2018 revenue 2017 figures boosted by sales from Petersen case and result of Teinver claim GKC acquisition adds revenue from 2017 onwards Interest Cover 20 No debt prior to 2014 Multiple of interest E 2018E 2019E Retail bond issues in 2014, 2016 and 2017 $43.75m loan note issued for GKC acquisition now redeemed 2014 issue was mid-year so only partial accrual of coupon EPS and dividend Underlying eps ($) Dividend ($) 2017 results boosted by sales from Petersen case Full effect of large single $100m investment coming through properly in late 2016 and into 2017 Some large single claims may increase volatility in the future E 2018E 2019E 0.00 Source: Company data; Hardman & Co 2

3 Effect of transaction The Teinver case is one of Burford s long standing investments, and is one of the three individual claims from the 2010 investments which are significant in size and are yet to be resolved. The matter is based on the expropriation of two airlines, Aerolíneas Argentinas and Austral, by the Argentinian government in At the time of expropriation, the government paid one peso in compensation, claiming the companies had negative worth and they were saving them. The arbitration process ultimately adopted the valuation from an international investment bank to come to the figure of $324m. Argentina has 90 days from the date of the ruling to decide whether to file for an annulment, the equivalent of an appeal for this form of arbitration. Historically it has tended to do so, though the grounds on which it can do so are narrower than for normal court cases. Despite the amount involved, the decision as to whether to file for annulment does not look straightforward. Strategically it makes sense to fight to discourage other cases. However, there will be additional costs in doing so. Politically, the government has already pinned the blame squarely on the preceding Kirchner regime. While we expect the government to file for annulment, we would not entirely be surprised if it does not. We understand that under the annulment process the ultimate timing of the decision is subject to the usual legal uncertainty, but most results are obtained within a couple of years. As part of this there may be discussions about a settlement. This is quite common, and could simplify the process and guarantee payment in return for a discount on the claim. Obviously, there can be no guarantee such discussions will take place or, if they do, whether they will lead to an outcome. All decisions remain with the claimants and are out of Burford s control, though we would expect some consultation to take place. The arbitration panel that is being used, International Centre for Settlement of Investment Disputes, is a part of the World Bank Group. Any results have the force of a High Court judgement and enforcing the claim, if that is necessary, should be straightforward. Although some parts of the press have made a connection with the Petersen case, the only overlap is the involvement of Argentina and there is no read-across from this result to that claim. Effect on Burford s financials Burford s policy is that they will not take the full amount of a claim where there is outstanding legal risk, something that clearly applies here. However, as an H2 event this will not be included in the interim results and Burford will not need to value it until the year end, when things may be clearer. The Burford part of the claim will accumulate interest over time, and we understand it will be at a rate in excess of that currently applicable to the overall claim. This means that even if the actual result is as announced, the amount payable to Burford, and its share of the overall claim, will increase over time. 3

4 Although there is pressure on analysts to make adjustments immediately, we are not going to do so on this occasion. The main reason is that our forecasts already contain significant figures for the Petersen case that are really educated guesswork. Also, we have already made assumptions for growth in the portfolio, and as yet we do not know if this is a big gain on top of another great year, or an offset to a weaker performance elsewhere in the portfolio. For both we will get much greater clarity on these when the interim results come out later this week. Summary This is clearly another piece of positive news for investors. Although it may still be some time before the actual amount is known and any cash paid, this looks to beanother substantial gain for Burford. It has taken seven years to get to this stage, and maybe two years or more before the final payment is received, but this case demonstrates the value of patience and a balance sheet that is strong enough to carry such claims. Although there is no direct read across to other cases, we note that Burford has other substantial claims that remain unresolved and have the potential to produce similar results. 4

5 Financials and Forecast We note, as before, that our revenue forecasts largely reflect an expected average based on analysis of Burford s track record. Individual cases are binary in nature and, therefore, impossible to explicitly forecast. As this announcement demonstrates, Burford has a few large cases, including the Petersen claim, which may have a significant but impossible to forecast impact on the results. Summary financials Year end Dec ($m) E 2018E 2019E Revenue Expenses Operating Profit Finance cost Exceptional items Reported pre-tax Reported taxation Minorities Underlying net income Statutory net income Underlying Basic EPS ($) Statutory Basic EPS ($) Dividend ($) Balance sheet Total equity Invested Capital Fair Value Balance , ,451.3 Total Assets , , ,563.6 NAV Per share ($) Return on Equity 12.4% 15.8% 21.0% 35.8% 15.9% 16.6% Source: Hardman & Co, 1=$1.27 5

6 Notes

7 Disclaimer Hardman & Co provides professional independent research services. Whilst every reasonable effort has been made to ensure that the information in the research is correct, this cannot be guaranteed. The research reflects the objective views of the analysts named on the front page. However, the companies or funds covered in this research may pay us a fee, commission or other remuneration in order for this research to be made available. A full list of companies or funds that have paid us for coverage within the past 12 months can be viewed at Hardman & Co has a personal dealing policy which debars staff and consultants from dealing in shares, bonds or other related instruments of companies which pay Hardman for any services, including research. They may be allowed to hold such securities if they were owned prior to joining Hardman or if they were held before the company appointed Hardman. In such cases sales will only be allowed in limited circumstances, generally in the two weeks following publication of figures. Hardman & Co does not buy or sell shares, either for its own account or for other parties and neither does it undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly, we do not publish records of our past recommendations. Where a Fair Value price is given in a research note this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities/companies but has no scheduled commitment and may cease to follow these securities/companies without notice. Nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell securities by us. This information is not tailored to your individual situation and the investment(s) covered may not be suitable for you. You should not make any investment decision without consulting a fully qualified financial adviser. This report may not be reproduced in whole or in part without prior permission from Hardman &Co. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority (FCA) under registration number Hardman Research Ltd is registered at Companies House with number However, the information in this research report is not FCA regulated because it does not constitute investment advice (as defined in the Financial Services and Markets Act 2000) and is provided for general information only. Hardman & Co Research Limited (trading as Hardman & Co) 35 New Broad Street London EC2M 1NH T +44 (0) Follow us on (Disclaimer Version 3 Effective from April 2017)

8 Hardman Team Management Team +44 (0) John Holmes +44 (0) Chairman Keith Hiscock +44 (0) CEO Marketing / Investor Engagement +44 (0) Richard Angus ra@hardmanandco.com +44 (0) Max Davey md@hardmanandco.com +44 (0) Antony Gifford ag@hardmanandco.com +44 (0) Vilma Pabilionyte vp@hardmanandco.com +44 (0) Gavin Laidlaw gl@hardmanandco.com +44 (0) Ann Hall ah@hardmanandco.com +44 (0) Analysts +44 (0) Agriculture Bonds Doug Hawkins dh@hardmanandco.com Brian Moretta bm@hardmanandco.com Yingheng Chen yc@hardmanandco.com Mark Thomas mt@hardmanandco.com Thomas Wigglesworth tcw@hardmanandco.com Chris Magennis cm@hardmanandco.com Building & Construction Consumer & Leisure Tony Williams tw@hardmanandco.com Mike Foster mf@hardmanandco.com Mike Foster mf@hardmanandco.com Steve Clapham sc@hardmanandco.com Jason Streets js@hardmanandco.com Financials Life Sciences Brian Moretta bm@hardmanandco.com Martin Hall mh@hardmanandco.com Mark Thomas mt@hardmanandco.com Gregoire Pave gp@hardmanandco.com Dorothea Hill dmh@hardmanandco.com Media Mining Derek Terrington dt@hardmanandco.com Paul Singer if@hardmanandco.com Oil & Gas Property Angus McPhail am@hardmanandco.com Mike Foster mf@hardmanandco.com Services Special Situations Mike Foster mf@hardmanandco.com Steve Clapham sc@hardmanandco.com Paul Singer ps@hardmanandco.com Tax Enhanced Services Utilities Brian Moretta bm@hardmanandco.com Nigel Hawkins nh@hardmanandco.com Chris Magennis cm@hardmanandco.com Hardman & Co 35 New Broad Street London EC2M 1NH Tel: +44(0)

City of London Investment Group

City of London Investment Group 20 th July 2017 Financial Services Daily CLIG.L 21/07/2015-29/08/2017 (LON) Line, CLIG.L, 20/07/2017, 429.10, N/A, N/A Price 429.10 GBp 420 410 400 390 380 370 360 350 340 330 320 310 300 290 280 A S O

More information

City of London Investment Group

City of London Investment Group 14 th September 2016 Financial Services Daily CLIG.L Line, CLIG.L, Trade Price(Last), 12/09/2016, 360.00, -11.50, (-3.10%) Source: Eikon Thomson Reuters Market data EPIC/TKR CLIG Price (p) 371.5 12m High

More information

Burford Capital. Financial summary and valuation

Burford Capital. Financial summary and valuation 19 th December 2016 Financials Daily BURF.L Line, BURF.L, Trade Price(Last), 29/07/2016, 391.00, -8.00, (-2.01%) 30/07/2014-28/07/2016 (LON) Price GBp 391.00 390 360 A S O N D J F M A M J J A S O N D J

More information

PPHE Hotel Group. Operating results in line. Financial summary and valuation

PPHE Hotel Group. Operating results in line. Financial summary and valuation 2 nd March 2018 Travel & Leisure Daily PPH.L Line, PPH.L, Trade Price(Last), 01/03/2018, 1,150.0000, -15.0000, (-1.30%) Source: Eikon Thomson Reuters Market data EPIC/TKR PPH Price (p) 1130 12m High (p)

More information

Non-Standard Finance

Non-Standard Finance 29 th November 2016 Financial Services Daily NSF.L Line, NSF.L, Trade Price(Last), 22/11/2016, 60.00N/A, N/A Source: Eikon Thomson Reuters Market data EPIC/TKR NSF Price (p) 60 12m High (p) 99.25 12m Low

More information

City of London Investment Group

City of London Investment Group 18 th September 2017 Financial Services Daily CLIG.L Line, CLIG.L, Trade Price(Last), 18/09/2017, 403.60, -1.50, (-0.38%) 24/12/2015-18/09/2017 (LON) Price GBp 420 410 403.60 400 390 380 370 City of London

More information

BURFORD CAPITAL. Financial summary and valuation

BURFORD CAPITAL. Financial summary and valuation 5 October 2018 Financials Daily BURF.L Line, BURF.L, Trade Price(Last), 05/10/2018, 1,794.0000, -24.0000, (-1.32%) 26/04/2016-04/10/2018 (LON) Price GBp 2,000 1,900 1,794.0000 1,800 1,700 1,600 1,500 1,400

More information

Arie Capital Technology EIS

Arie Capital Technology EIS 21 st September 2017 Arie Capital Technology EIS Summary Why Invest Arie Tech LLP / Sapphire Capital Partners LLP The fund s investment strategy is to invest in a portfolio of EIS qualifying technology

More information

Tissue Regenix. Dual revenue stream growth. Financial summary and valuation

Tissue Regenix. Dual revenue stream growth. Financial summary and valuation 11 th October 2017 Pharmaceuticals & Biotechnology Dual revenue stream growth Source: Eikon Thomson Reuters Market data EPIC/TKR TRX Price (p) 11.0 12m High (p) 21.0 12m Low (p) 10.7 Shares (m) 1161.8

More information

Morses Club. Building a profitable and sustainable franchise. 20 th October Financial summary and valuation. Financial Services

Morses Club. Building a profitable and sustainable franchise. 20 th October Financial summary and valuation. Financial Services 20 th October 2017 Financial Services Daily MCLM.L Line, MCLM.L, Trade Price(Last), 06/10/2017, 140.885, +1.750, (+1.23%) Source: Eikon Thomson Reuters Market data EPIC/TKR MCL Price (p) 134.0 12m High

More information

Aramco IPO. Timing. By Steve Clapham, Hardman & Co Analyst

Aramco IPO. Timing. By Steve Clapham, Hardman & Co Analyst August 2017 Aramco IPO By Steve Clapham, Hardman & Co Analyst Source: Creative Commons An IPO of Saudi Aramco in late 2018 at a valuation of $2 trillion (tn) has been widely trailed in the Press. Although

More information

Morses Club PLC (MCL)

Morses Club PLC (MCL) 25 th May 2017 Financials Daily MCLM.L Line, MCLM.L, Trade Price(Last), 24/05/2017, 134.00, N/A, N/A Source: Eikon Thomson Reuters Market data EPIC/TKR MCL Price (p) 134.0 12m High (p) 136.1 12m Low (p)

More information

MiFID II Monitor. Assessing the impact so far. Revisiting the issue of stock liquidity. August 2018

MiFID II Monitor. Assessing the impact so far. Revisiting the issue of stock liquidity. August 2018 August 2018 Monitor Assessing the impact so far By Keith Hiscock CEO and Yingheng Chen, Hardman & Co Analyst and examining initial effect of Source: istock Revisiting the issue of stock liquidity Hardman

More information

Table of Contents. EMV EIS Fund I

Table of Contents. EMV EIS Fund I 13 th November 2017 EMV EIS Fund I Summary Why Invest EcoMachines Ventures Ltd / Sapphire Capital Partners LLP The fund s investment strategy is to invest in a portfolio of EIS qualifying technology companies,

More information

Mercia Growth Fund 8

Mercia Growth Fund 8 31 st July 2017 Mercia Growth Fund 8 Mercia Fund Management Limited Summary The fund s investment strategy is to invest in a diverse portfolio of EIS Qualifying companies, with an option to include SEIS,

More information

Collagen Solutions. Financial summary and valuation

Collagen Solutions. Financial summary and valuation 21 st December 2016 Healthcare equipment/services Collagen Solutions Interims: Foundations laid for strategic growth Source: Eikon Thomson Reuters Market data EPIC/TKR COS Price (p) 5.00 12m High (p) 14.75

More information

PPHE (PPH.L) Sterling start to the year

PPHE (PPH.L) Sterling start to the year 11th May 2015 PPHE (PPH.L) Sterling start to the year PPHE, the owner and operator of Park Plaza hotels in Europe, has reported a strong start to the new year with Q1 revenue +12.5%, despite lapping a

More information

2017: a pivotal year. Financial summary and valuation

2017: a pivotal year. Financial summary and valuation 20 th April 2018 Pharmaceuticals & Biotechnology ValiRx 2017: a pivotal year Source: Eikon Thomson Reuters Market data EPIC/TKR VAL Price (p) 3.00 12m High (p) 7.30 12m Low (p) 0.96 Shares (m) 133.36 Mkt

More information

Sinclair Pharma. Financial summary and valuation

Sinclair Pharma. Financial summary and valuation 2 nd October 2017 Pharmaceuticals & Biotechnology Sinclair Pharma Demand growing in target markets Source: Eikon Thomson Reuters Market data EPIC/TKR SPH Price (p) 26.1 12m High (p) 36.4 12m Low (p) 26.0

More information

Calculus EIS Fund. Calculus Capital Limited

Calculus EIS Fund. Calculus Capital Limited 28 th February 2018 Calculus EIS Fund Summary Calculus Capital Limited This is the 18 th EIS fund that Calculus have launched. The fund will mostly invest in more established businesses, with demonstrable

More information

Alliance Pharma. Kelo-cote building international sales. Financial summary and valuation

Alliance Pharma. Kelo-cote building international sales. Financial summary and valuation 17 th October 2017 Pharmaceuticals & Biotechnology Alliance Pharma Kelo-cote building international sales Source: Eikon Thomson Reuters Market data EPIC/TKR APH Price (p) 59.0 12m High (p) 60.0 12m Low

More information

An explosion of accounting fraud

An explosion of accounting fraud August 2018 An explosion of accounting fraud By Steve Clapham, Hardman & Co Analyst Source: Shutterstock Disclaimer: Attention of readers is drawn to important disclaimers printed at the end of this document

More information

Eden Rock Ventures. Eden Rock Capital Management LLP

Eden Rock Ventures. Eden Rock Capital Management LLP 08 th June 2018 Eden Rock Ventures Eden Rock Capital Management LLP Summary The fund s investment strategy is to invest in a diverse portfolio of EIS qualifying investments in selected technology or technology-enabled

More information

Par Syndicate EIS Fund

Par Syndicate EIS Fund 8 May 2018 Par Syndicate EIS Fund Par Fund Management Limited Summary Why Invest The Investment Manager The fund s investment strategy is to invest in EIS Qualifying companies involved in the development,

More information

Deepbridge Innovation SEIS

Deepbridge Innovation SEIS 8 th March 2018 Deepbridge Advisers Limited/Enterprise Investment Partners Summary Why Invest The is a discretionary portfolio service that will invest into a small portfolio of up to 10 underlying companies,

More information

International Ambulances Ltd

International Ambulances Ltd 9 th May 2017 Full EIS Report International Ambulances Ltd Gold Due Diligence for GrowthInvest International Ambulances is designing and building a new ambulance which will be the first that is designed

More information

Start-Up Series SEIS Fund One

Start-Up Series SEIS Fund One 7 th November 2016 Summary Start-Up Series SEIS Fund One Worth Capital / Amersham Investment Management The Fund s investment strategy is to invest in a portfolio of SEIS qualifying companies sourced through

More information

Nexus Investments Scale-Up Fund

Nexus Investments Scale-Up Fund 1 August 2018 Nexus Investments Scale-Up Fund Nexus Investment Management Limited Summary The fund s investment strategy is to invest in a diverse portfolio of EIS-qualifying investments in data, digital,

More information

Single company EIS report

Single company EIS report 7 th September 2017 12x3 s Limited Single company EIS report Summary 12x3 s is raising new money to fund the growth of its first boxing gym and the establishment of its second. Why Invest The Management

More information

Morses Club. Financial summary and valuation

Morses Club. Financial summary and valuation 16 May 2018 Financial Services Daily MCLM.L Line, MCLM.L, Trade Price(Last), 09/05/2018, 154.8000, N/A, N/A Source: Eikon Thomson Reuters Market data EPIC/TKR MCL Price (p) 152.75 12m High (p) 154.8 12m

More information

Non-Standard Finance

Non-Standard Finance 27 th March 2018 Financials Daily NSF.L Line, NSF.L, Trade Price(Last), 23/03/2018, 63.000, N/A, N/A 29/03/2016-23/03/2018 (LON) Price GBp 78 76 74 72 70 68 Non-Standard Finance Strong profit growth path

More information

Deepbridge Life Sciences SEIS

Deepbridge Life Sciences SEIS 9 th March 2018 Deepbridge Advisers Limited/Enterprise Investment Partners Summary Why Invest The is a discretionary portfolio service that will invest into a small portfolio of up to 10 underlying companies,

More information

Deepbridge Life Sciences EIS

Deepbridge Life Sciences EIS 7 th March 2018 Deepbridge Life Sciences EIS Deepbridge Advisers Limited/Enterprise Investment Partners Summary Why Invest The Deepbridge Life Sciences EIS is a discretionary portfolio service that will

More information

Sinclair Pharma. Much more streamlined. Financial summary and valuation

Sinclair Pharma. Much more streamlined. Financial summary and valuation 28 th March 2017 Pharmaceuticals & Biotechnology Sinclair Pharma Much more streamlined Source: Eikon Thomson Reuters Market data EPIC/TKR SPH Price (p) 32.5 12m High (p) 41.0 12m Low (p) 26.0 Shares (m)

More information

Advanced Oncotherapy

Advanced Oncotherapy 15 th March 2017 Healthcare Equipment & Services Advanced Oncotherapy Delivery of LIGHT Source: Eikon Thomson Reuters Market data EPIC/TKR AVO Price (p) 43.0 12m High (p) 209.0 12m Low (p) 44.0 Shares

More information

Collagen Solutions plc

Collagen Solutions plc 14 th September 2015 Healthcare Equipment & Services Collagen Solutions plc Product acquisition regenerative medicine Source: Fidessa Market data EPIC COS Price (p) 12.10 12m High (p) 14.75 12 Low (p)

More information

Allergy Therapeutics

Allergy Therapeutics 20 th January 2017 Pharmaceuticals & Biotechnology Allergy Therapeutics Investment driving market share gains Source: Eikon Thomson Reuters Market data EPIC/TKR AGY Price (p) 24.0 12m High (p) 28.5 12m

More information

CITY OF LONDON INVESTMENT GROUP

CITY OF LONDON INVESTMENT GROUP 21 January 2019 Financial Services Daily CLIG.L Line, CLIG.L, Trade Price(Last), 21/01/2019, 384.20, +11.00, (+2.90%) 23/01/2017-21/01/2019 (LON) Price GBp CITY OF LONDON INVESTMENT GROUP F M A M J J A

More information

Alliance Pharma. 2017: strong operational cashflow. Financial summary and valuation

Alliance Pharma. 2017: strong operational cashflow. Financial summary and valuation 29 th January 2018 Pharmaceuticals & Biotechnology Alliance Pharma 2017: strong operational cashflow Source: Eikon Thomson Reuters Market data EPIC/TKR APH Price (p) 69.6 12m High (p) 71.4 12m Low (p)

More information

Titon Holdings Plc. Over the moon. Financial summary and valuation

Titon Holdings Plc. Over the moon. Financial summary and valuation 18 th December 2017 Construction & Materials Daily TITN.L Line, TITN.L, Trade Price(Last), 13/12/2017, 151.50, +7.00, (+4.62%) 15/12/2015-13/12/2017 (LON) J F M A M J J A S O N D J F M A M J J A S O N

More information

Tissue Regenix. Full-year 2017: what to look for. Financial summary and valuation

Tissue Regenix. Full-year 2017: what to look for. Financial summary and valuation 8 th March 2018 Pharmaceuticals & Biotechnology Tissue Regenix Full-year 2017: what to look for Source: Eikon Thomson Reuters Market data EPIC/TKR TRX Price (p) 8.8 12m High (p) 18.3 12m Low (p) 5.5 Shares

More information

CITY OF LONDON INVESTMENT GROUP

CITY OF LONDON INVESTMENT GROUP 9 October 2018 Financial Services Daily CLIG.L Line, CLIG.L, Trade Price(Last), 09/10/2018, 409.00, N/A, N/A Market data Source: Eikon Thomson Reuters EPIC/TKR CLIG Price (p) 400.0 12m High (p) 454.0 12m

More information

UK Housebuilding Sector: Q2 2017

UK Housebuilding Sector: Q2 2017 6 th July 2017 UK Housebuilding Sector: Q2 2017 Summer 2017 The Peak District Source: Creative Commons Analyst Tony Williams 020 7194 7622 tw@hardmanandco.com Disclaimer: Attention of readers is drawn

More information

Oxford BioMedica. Financial summary and valuation

Oxford BioMedica. Financial summary and valuation 20 September 2018 Pharmaceuticals & Biotechnology Daily OXB.L Line, OXB.L, Trade Price(Last), 20/09/2018, 900.80, +0.80, (+0.09%) Source: Eikon Thomson Reuters Market data EPIC/TKR OXB Price (p) 900.0

More information

UK Housebuilding Sector: Q1 2017

UK Housebuilding Sector: Q1 2017 10 th April 2017 UK Housebuilding Sector: Q1 2017 Spring 2017 Births, Brexit, Bovis bids Source: istock, Shutterstock, Creative Commons Source Analyst Tony Williams 020 7929 3399 tw@hardmanandco.com Disclaimer:

More information

UK Housebuilding Sector. Eat My Shorts, Man!

UK Housebuilding Sector. Eat My Shorts, Man! Q1: Spring 2016 Eat My Shorts, Man! The Simpsons, as if you didn t know, is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. It is a satirical depiction of a working

More information

Alliance Pharma. Financial summary and valuation

Alliance Pharma. Financial summary and valuation 11 th January 2018 Pharmaceuticals & Biotechnology Alliance Pharma Acquisitions to boost growth prospects Source: Eikon Thomson Reuters Market data EPIC/TKR APH Price (p) 67.0 12m High (p) 67.7 12m Low

More information

GENEDRIVE PLC Preventing hearing loss in newborns

GENEDRIVE PLC Preventing hearing loss in newborns 27 June 2018 Pharmaceuticals & Biotechnology Source: Eikon Thomson Reuters Market data EPIC/TKR GDR Price (p) 36.4 12m High (p) 42.5 12m Low (p) 25.0 Shares (m) 18.9 Mkt Cap ( m) 6.9 EV ( m) 9.2 Free Float*

More information

Retail Bond Review No. 10

Retail Bond Review No. 10 28 th October 2015 FTSE ORB Index Retail Bond Review No. 10 145 140 135 Feature Article: Bond Structuring 130 125 120 115 Sep 13 Dec 13 Mar 14 Jun 14 Sep 14 Dec 14 Mar 15 Jun 15 Sep 15 For many investors

More information

The Good, the Bad and the Ugly:

The Good, the Bad and the Ugly: The Good, the Bad and the Ugly: UK housebuilding Sector, a review of 2014; and a look yonder Winter 2014/2015 Analyst Tony Williams +44 (0)207 929 3399 research@hardmanandco.com Sales & Marketing Max Davey

More information

Lombard Risk Management (LRM.L)

Lombard Risk Management (LRM.L) 20 th October 2014 14 LRM LOMBARD RISK ORD 0.5P Lombard Risk Management (LRM.L) 13 12 11 Riding the regulatory surge: Interim results 10 Q4-2013 Q1-2014 Q2-2014 Q3-2014 Source: Fidessa Price: 12.5p 12m

More information

Investor Presentation

Investor Presentation Investor Presentation Burford Capital Limited 1H 2017 Results This presentation is for the use of Burford s public shareholders and is not an offering of any Burford private fund. Burford Capital is the

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION 2017 RESULTS 14 MARCH 2018 This presentation is for the use of Burford s public shareholders and is not an offering of any Burford private fund. Third-party litigation funding is

More information

RETAIL BOND REVIEW No. 2

RETAIL BOND REVIEW No. 2 24 th October 2013 A solid quarter for the ORB Over quarter, FTSE ORB index rose 2.6% One new issue during the quarter raising 50m Yield curve for bonds in FTSE ORB Index as at 30 September 2013 RETAIL

More information

Smith s is an independent corporate finance advisory firm whose advice is built on a continuing dialogue with institutional investors.

Smith s is an independent corporate finance advisory firm whose advice is built on a continuing dialogue with institutional investors. Smith s is an independent corporate finance advisory firm whose advice is built on a continuing dialogue with institutional investors. Contents: Introduction Page 4 Conclusion Page 6 Synopsis of results

More information

IndigoVision Group (IND LN)

IndigoVision Group (IND LN) I ndigovision Grou p Interim Results IndigoVision Group (IND LN) IT Hardware Current price* 117p CORPORATE Losses narrowing and guidance reiterated FY18 is expected to be a year of stabilisation and management

More information

Evaluation of a Real Estate Investment Trust: A Homemade Process

Evaluation of a Real Estate Investment Trust: A Homemade Process Evaluation of a Real Estate Investment Trust: A Homemade Process Introduction (Beattie, 2009) Real estate has been around since our cave-dwelling ancestors started chasing strangers out of caves, so it's

More information

INTERIMS: ADEPT TELECOM

INTERIMS: ADEPT TELECOM This research is intended for UK institutional investors only. It is not intended for retail customers and any retail customer should seek professional, independent advice before investing. TELECOMMUNICATIONS

More information

About Burford Capital

About Burford Capital Interim Report 2013 About Burford Capital Burford Capital is the world s largest provider of investment capital and risk solutions for litigation with the largest and most experienced dedicated team in

More information

Revolution Bars Group plc (LSE: RBG) Interim results for the six months ended 31 December 2016

Revolution Bars Group plc (LSE: RBG) Interim results for the six months ended 31 December 2016 28 February 2017 Revolution Bars Group plc (LSE: RBG) Interim results for the six months ended 31 2016 Revolution Bars Group plc ( the Group ), a leading UK operator of premium bars, trading under the

More information

City of London Investment Group*

City of London Investment Group* For FCA purposes this is a Marketing Communication City of London Investment Group* CLIG LN Tough 1H trading update Financials What s new. CLIG s 1H trading update released this morning reveals details

More information

Unicorn AIM VCT plc January 2015

Unicorn AIM VCT plc January 2015 Unicorn AIM VCT plc January 2015 Introduction to AIM The Alternative Investment Market (AIM) is the world s leading market for smaller, growing companies from across the globe. It offers companies from

More information

Pirelli & C Real Estate

Pirelli & C Real Estate ENN Europe Italy Real Estate 11 Nov 2004 Deutsche Bank Pirelli & C Real Estate Real Estate, Reloaded Recommendation Hold Price at 10 Nov 2004 EUR 35.00 Target Price EUR 39.20 Ticker/Code PCRE.MI Year End

More information

Desperately seeking diversification

Desperately seeking diversification Why and how should you diversify your growth assets? Summary Suitably diversified growth asset portfolios have better risk-return profiles than narrow portfolios but, in practice, formulating and implementing

More information

2014 E 2015 E 2016 E 2017 E

2014 E 2015 E 2016 E 2017 E Equity Research 4 December 2014 Interpump Group Hydraulics M&A may power growth Rating BUY Target price EUR13 Interpump is up 25% since the beginning of the year, bolstered by strong interim results and

More information

The Monthly. August Feature article: Aramco IPO. by Steve Clapham, Hardman & Co Analyst. Geopolitical worries about the oil price

The Monthly. August Feature article: Aramco IPO. by Steve Clapham, Hardman & Co Analyst. Geopolitical worries about the oil price 1 st August 2017 The Monthly August 2017 Feature article: Aramco IPO by Steve Clapham, Hardman & Co Analyst Company Coverage Abzena Advanced Oncotherapy Allergy Therapeutics Alliance Pharma Arbuthnot Banking

More information

The "Shell" Transport and Trading Company

The Shell Transport and Trading Company The "Shell" Transport and Trading Company Public Limited Company 19 September 1995 Mr A E Donovan Maple Bank 4 Parkside Ixer Lane Bradfield Combust, Suffolk Direct lines: Tel: 01719343080 Fax: 01719347043

More information

Falanx Group Ltd. 16 October

Falanx Group Ltd. 16 October Stock Data Share Price: 2.95p Market Cap.: 7.7m Shares in issue: 261.9m Company Profile Sector: Ticker: Exchange: Support Services FLX.L AIM Activities Provider of cyber defence, security and global intelligence

More information

Burford Capital Limited NOTICE OF GENERAL MEETING. Adoption of long term incentive plan

Burford Capital Limited NOTICE OF GENERAL MEETING. Adoption of long term incentive plan THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to any aspect of the proposals referred to in this document or as to the action you should take, you should

More information

SUPPLEMENT NO November 2016

SUPPLEMENT NO November 2016 The directors of IVI Umbrella Fund plc (the Directors ) listed in the Prospectus dated 1 November 2016 (the Prospectus ) in the Management and Administration section, accept responsibility for the information

More information

Chinasoft International (0354 HK)

Chinasoft International (0354 HK) Equity Research Tech, Media & Telecom 11 Jun 2014 Chinasoft International (0354 HK) SaaS initiative in cloud business Advancing in SaaS cloud with government and corporates demand: Following exclusive

More information

Commerzbank Energy & Carbon Seminar

Commerzbank Energy & Carbon Seminar Commerzbank Energy & Carbon Seminar Trends, challenges and outlook for the energy and carbon markets in 2016 marketing material for information purposes only Ingo Ramming A 5 bet on Leicester City winning

More information

Managed portfolio service

Managed portfolio service 1 Managed portfolio service The value of investments and the income from them may go down as well as up and you may not get back your original investment. Past performance should not be seen as an indication

More information

JPMorgan Smaller Companies Investment Trust plc Annual General Meeting

JPMorgan Smaller Companies Investment Trust plc Annual General Meeting JPMorgan Smaller Companies Investment Trust plc Annual General Meeting 28 November 2017 Georgina Brittain, Portfolio Manager Katen Patel, Portfolio Manager Agenda Introduction Performance Review Current

More information

ANZ-ROY MORGAN AUSTRALIAN CONSUMER CONFIDENCE MEDIA RELEASE. Figure 1. ANZ-Roy Morgan Australian Consumer Confidence and inflation expectations

ANZ-ROY MORGAN AUSTRALIAN CONSUMER CONFIDENCE MEDIA RELEASE. Figure 1. ANZ-Roy Morgan Australian Consumer Confidence and inflation expectations ANZ RESEARCH ANZ-ROY MORGAN AUSTRALIAN CONSUMER CONFIDENCE MEDIA RELEASE 17 APRIL 2018 CONTACT research@anz.com CONTRIBUTORS Mustafa Arif Junior Economist +91 80 6795 3801 mustafa.arif@anz.com David Plank

More information

Hardman Monthly July 2016

Hardman Monthly July 2016 1 st July 2016 Hardman Monthly July 2016 Feature article: EU Telcos Heroic Value Destruction Company Coverage: Allergy Therapeutics In recent years, various sectors have seen dreadful share price performances,

More information

Arbuthnot Banking Group Acquisition of Everyday Loans

Arbuthnot Banking Group Acquisition of Everyday Loans Arbuthnot Banking Group Acquisition of Everyday Loans Capitalising opportunities Financials In line with its stated strategy, Arbuthnot Banking Group s (ABG) 75.5% subsidiary Secure Trust Bank (STB) has

More information

Agenda Registration and lunch Introduction by Julian Marr

Agenda Registration and lunch Introduction by Julian Marr Agenda 12.00 13.00 Registration and lunch 13.00 13.10 Introduction by Julian Marr 13.10 13.35 Presentation by Robin McDonald Cazenove Capital Management 13.35 13.55 Presentation by Tony Lanning Gartmore

More information

HEDGE ACCOUNTING UPDATE: New Dollar Offset Theta (DOT): An evolution in hedge accounting methodology? [Technical]

HEDGE ACCOUNTING UPDATE: New Dollar Offset Theta (DOT): An evolution in hedge accounting methodology? [Technical] Discussion document JULY 218 HEDGE ACCOUNTING UPDATE: New Dollar Offset Theta (DOT): An evolution in hedge accounting methodology? [Technical] by Adam Piers Bridgewater Discussions with clients and their

More information

buy list update UK EQUITIES Invesco Perpetual Income & Growth Invesco Perpetual Income & Invesco Perpetual High Income November 2017 SELL:

buy list update UK EQUITIES Invesco Perpetual Income & Growth Invesco Perpetual Income & Invesco Perpetual High Income November 2017 SELL: buy list update November 2017 The clarity investment committee regularly reviews the funds on our buy list and has recently made some changes, mainly in relation to UK and AsiaPacific funds, as summarised

More information

Indostar Capital Finance

Indostar Capital Finance January 2, 2019 Buy Indostar Capital Finance Industry: BFSI Fallen, but not beaten down!!! We recently interacted with the management to get an understanding of the recent developments of the company post

More information

BUY Price at COB 1 October p 52-week range 39-68p. CSF Group CX6 restructuring. Technology.

BUY Price at COB 1 October p 52-week range 39-68p. CSF Group CX6 restructuring. Technology. 70 65 60 55 50 45 40 35 C SF G R O U P O N D J F M A M J J A S So u r c e : T h o m s o n R e u te r s D a ta s tr e a m Technology 2 October 2012 International Update CSF Group CX6 restructuring CSF has

More information

DX (Group) plc* Industrial Transportation. Successful HMPO tender improves forecast certainty. Price 17.75p. Price Performance. Financial Forecasts

DX (Group) plc* Industrial Transportation. Successful HMPO tender improves forecast certainty. Price 17.75p. Price Performance. Financial Forecasts For FCA purposes this is a Marketing Communication DX (Group) plc* DX. LN Industrial Transportation Successful HMPO tender improves forecast certainty DX has confirmed that it has won the retendering of

More information

Key estimate revision. Financial summary. Year

Key estimate revision. Financial summary. Year : price: ABV: How does our one year outlook change? Retain our positive view on the stock. We continue to believe that SUF is a multi-year compounding opportunity in the asset and home financing segments.

More information

Company no Charity no Global Witness Trust Report and Financial Statements 31 December 2017

Company no Charity no Global Witness Trust Report and Financial Statements 31 December 2017 Company no. 05883832 Charity no. 1117844 Global Witness Trust Report and Financial Statements 31 December 2017 Reference and administrative details Company number 05883832 Charity number 1117844 Registered

More information

About Burford Capital

About Burford Capital Interim Report 2014 About Burford Capital Burford Capital is the world s largest provider of investment capital and risk solutions for litigation with the largest and most experienced dedicated team in

More information

Company Overview. Industry Overview. Financial Performance

Company Overview. Industry Overview. Financial Performance Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 Jan/16 Trade Wings Limited CMP: 105.00 January 29, 2016 Stock Details BSE code 509953 BSE ID TRADWIN Face value ( ) 10 No of

More information

ANZ appoints Hongkong and Shanghai Bank s Michael Smith to succeed John McFarlane on 1 October 2007

ANZ appoints Hongkong and Shanghai Bank s Michael Smith to succeed John McFarlane on 1 October 2007 For Release: 12 June 2007 Corporate Communications 100 Queen Street Melbourne Vic 3000 www.anz.com ANZ appoints Hongkong and Shanghai Bank s Michael Smith to succeed John McFarlane on 1 October 2007 Mr

More information

CIRCULAR. No JULY 2007 PRACTITIONER & EMPLOYER TRAINING EVENTS (1) INTRODUCTION (2) THE 2008 SCHEME CHANGES SEMINARS

CIRCULAR. No JULY 2007 PRACTITIONER & EMPLOYER TRAINING EVENTS (1) INTRODUCTION (2) THE 2008 SCHEME CHANGES SEMINARS The Local Government Pensions Committee Secretary: Terry Edwards CIRCULAR Please pass on sufficient copies of this Circular to your Treasurer/Director of Finance and to your Personnel and Pensions Officer(s)

More information

Bur for d Capi 2 t I N T E R I 0 M R E P O R 1 T 8 al Int erim Repor t 2 018

Bur for d Capi 2 t I N T E R I 0 M R E P O R 1 T 8 al Int erim Repor t 2 018 INTERIM REPORT About Burford Capital Burford Capital is a leading global finance and investment management firm focused on law. Its businesses include litigation finance and risk management, asset recovery

More information

For personal use only

For personal use only ASX/Media Release For immediate release 15 November 2017 2017 Annual General Meeting Energy Action Limited (ASX: EAX) is today holding its 2017 Annual General Meeting commencing at 2.00pm (AEDT). In accordance

More information

Company Overview. Financial Performance

Company Overview. Financial Performance Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 Jan/16 Feb/16 Mar/16 Monarch Networth Capital Limited CMP: 26.00 March 23, 2016 Stock Details BSE code 511551 BSE ID MONARCH Face value (

More information

Equity Research DAILY COMMENT

Equity Research DAILY COMMENT Equity Research DAILY COMMENT NTG CLARITY NETWORKS INC. NCI-V, $0.275 October 24, 2014 Rating: STRONG BUY Target Price: $1.00 Market Capitalization: $9.9M Risk Profile: SPECULATIVE TECHNOLOGY SOFTWARE

More information

52-Week High Trailing PE Week Low Forward PE Buy 8 Analysts. 1-Year Return: 1.1% 5-Year Return: 73.1%

52-Week High Trailing PE Week Low Forward PE Buy 8 Analysts. 1-Year Return: 1.1% 5-Year Return: 73.1% FIERA CAPITAL CORP (-T) Last Close 13.07 (CAD) Avg Daily Vol 115,974 52-Week High 15.20 Trailing PE 76.9 Annual Div 0.72 ROE 2.8% LTG Forecast -- 1-Mo -8.0% November 28 TORONTO Exchange Market Cap (Consol)

More information

For personal use only

For personal use only ENEABBA GAS LIMITED ACN 107 385 884 SHORT FORM PROSPECTUS For an offer to transfer 55,000,000 UIL Class A Convertible Preference Shares and 35,000,000 UIL Class B Convertible Preference Shares to Shareholders

More information

BRAIT SE Sector: Financials Max Sector Weight: 35%

BRAIT SE Sector: Financials Max Sector Weight: 35% Company Results Analysis 20 November 2017 Recommendation: Overweight JSE Capped SWIX weighting: 0.32% Recommended exposure up to: 5.32% BRAIT SE Sector: Financials Max Sector Weight: 35% Nature of Business:

More information

Bushveld Minerals* Increases underlying interest in Vametco to 75% Company update. 13 September Mining & Metals

Bushveld Minerals* Increases underlying interest in Vametco to 75% Company update. 13 September Mining & Metals Company update 13 September 2018 BMN LN Mining & Metals Bushveld Minerals* Increases underlying interest in Vametco to 75% Market data Source: LSE Price (p) 19.0 12m High (p) 28.5 12m Low (p) 7.6 Shares

More information

Axis Bank Ltd. For private circulation only. Volume No.. III Issue No October 08, 2018

Axis Bank Ltd. For private circulation only. Volume No.. III Issue No October 08, 2018 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Volume No.. III Issue No. 188. Axis Bank Ltd. October 08, 2018 BSE Code: 532215 NSE Code: AXISBANK Reuters Code:

More information

Year-end March 2012A 2013A 2014E 2015E Key Data Revenue ( m) Rating (12 month) BUY*

Year-end March 2012A 2013A 2014E 2015E Key Data Revenue ( m) Rating (12 month) BUY* This research is intended for UK institutional investors only and market professionals. It is not intended for retail customers and any retail customer should seek professional, independent advice before

More information